Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results.
AffiliationUniversity Hospital Rotterdam, Department of Pulmonary Diseases. P.O. Box 5201, 3008 AE Rotterdam, The Netherlands.
MetadataShow full item record
AbstractPatients who are treated within clinical trials may have a survival benefit dependent on being a trial participant. A number of factors may produce such beneficial outcome including more rigorous adherence to a peer reviewed trial protocol, management by an experienced treatment team, being treated in a specialist centre etc. The current investigation compared patients treated on and off trial with the same standard arm treatment regimen. The results could then be interpreted without the confounding factors of differing treatment regimens, treatment teams or treatment hospitals. The results demonstrated given these circumstances that survival was no different for patients participating in a randomised trial compared with a group of patients similarly treated who were not eligible for trial entry or who declined randomisation. These results were obtained by the rigorous adherence to a defined protocol with the invaluable assistance of designated lung cancer staff.
CitationIdentical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results. 2002, 87 (5):562-6 Br. J. Cancer
JournalBritish Journal of Cancer
- Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
- Authors: Joss RA, Bacchi M, Hürny C, Bernhard J, Cerny T, Martinelli G, Leyvraz S, Senn HJ, Stahel R, Siegenthaler P
- Issue date: 1995 Feb
- Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
- Authors: Joss RA, Alberto P, Hürny C, Bacchi M, Leyvraz S, Thürlimann B, Cerny T, Martinelli G, Stahel R, Ludwig C
- Issue date: 1995 Jan
- Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
- Authors: Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D
- Issue date: 1999 Aug
- Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
- Authors: Osterlind K, Hansen M, Hirsch FR, Dombernowsky P, Sörenson S, Pedersen AG, Hansen HH
- Issue date: 1991 Jan
- A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
- Authors: Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R
- Issue date: 1997 Dec 15